Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GAByMartin David HarpDecember 3rd 2025
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%ByMartin David HarpDecember 2nd 2025
The Art and Science of Presbyopia Correction: Navigating the IOL Patient JourneyByMatt Hoffman,Zach R. Balest, MD,Lisa K. Feulner, MD, PhDDecember 2nd 2025
Eydenzelt, Celltrion’s biosimilar referencing Eylea, approved in CanadaByMartin David HarpDecember 2nd 2025
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZByMartin David HarpDecember 2nd 2025